Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2021
Historique:
received: 21 05 2021
accepted: 06 07 2021
revised: 29 07 2021
pubmed: 20 7 2021
medline: 6 8 2021
entrez: 19 7 2021
Statut: epublish

Résumé

SARS-CoV-2 infection presents clinical manifestations ranging from asymptomatic to fatal respiratory failure. Despite the induction of functional SARS-CoV-2-specific CD8+ T-cell responses in convalescent individuals, the role of virus-specific CD8+ T-cell responses in the control of SARS-CoV-2 replication remains unknown. In the present study, we show that subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. Eight macaques were intranasally inoculated with 105 or 106 TCID50 of SARS-CoV-2, and three of the eight macaques were treated with a monoclonal anti-CD8 antibody on days 5 and 7 post-infection. In these three macaques, CD8+ T cells were undetectable on day 7 and thereafter, while virus-specific CD8+ T-cell responses were induced in the remaining five untreated animals. Viral RNA was detected in nasopharyngeal swabs for 10-17 days post-infection in all macaques, and the kinetics of viral RNA levels in pharyngeal swabs and plasma neutralizing antibody titers were comparable between the anti-CD8 antibody treated and untreated animals. SARS-CoV-2 RNA was detected in the pharyngeal mucosa and/or retropharyngeal lymph node obtained at necropsy on day 21 in two of the untreated group but undetectable in all macaques treated with anti-CD8 antibody. CD8+ T-cell responses may contribute to viral control in SARS-CoV-2 infection, but our results indicate possible containment of subacute viral replication in the absence of CD8+ T cells, implying that CD8+ T-cell dysfunction may not solely lead to viral control failure.

Identifiants

pubmed: 34280241
doi: 10.1371/journal.ppat.1009668
pii: PPATHOGENS-D-21-01073
pmc: PMC8321216
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009668

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Pathog. 2015 Nov 04;11(11):e1005247
pubmed: 26536034
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Biochem Biophys Res Commun. 2021 Jan 29;538:125-131
pubmed: 33218685
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Virol. 2014 Oct;88(19):11034-44
pubmed: 25056892
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Nat Commun. 2021 Feb 24;12(1):1260
pubmed: 33627662
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217
pubmed: 33190827
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33427749
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Sci Transl Med. 2021 May 12;13(593):
pubmed: 33820835
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292

Auteurs

Takushi Nomura (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Hiroyuki Yamamoto (H)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Masako Nishizawa (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Trang Thi Thu Hau (TTT)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Shigeyoshi Harada (S)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Hiroshi Ishii (H)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Sayuri Seki (S)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Midori Nakamura-Hoshi (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Midori Okazaki (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Sachie Daigen (S)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Ai Kawana-Tachikawa (A)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

Noriyo Nagata (N)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Naoko Iwata-Yoshikawa (N)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Nozomi Shiwa (N)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Shun Iida (S)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Harutaka Katano (H)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Tadaki Suzuki (T)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Eun-Sil Park (ES)

Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.

Ken Maeda (K)

Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.

Yuriko Suzaki (Y)

Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo, Japan.

Yasushi Ami (Y)

Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo, Japan.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH